Bremelanotide
Shop BremelanotideAlso called: PT-141, Vyleesi, Oxytocin PT-141 Peptide Stack
Bremelanotide is a man-made copy of a tiny protein-like molecule. It is also known by the code name PT-141. It was made to work on brain signals that affect sexual desire. Doctors and scientists study it, and some adults seek it out for low sex drive.
It works inside a part of the brain that controls arousal. It turns on special receivers called melanocortin receptors, which send signals that can boost sexual interest. In studies it has been tested for a problem called low sexual desire in women. It has also been looked at for men with arousal problems.
There is still a lot scientists do not know for sure, especially outside of official medical use. People who buy it online may get products that are not tested for safety or purity. It can cause side effects like nausea and can raise blood pressure. Anyone thinking about using it should talk to a doctor first, since only a real medical check can tell if it is safe.
Benefits
What Bremelanotide Helps With
The main themes across 40 research studies, in plain language.
Glycemic & metabolic
Metabolic & appetite regulation
40/100Rated 40/100Source typeVendor / seller pageIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 5 underlying claimsPreclinical and exploratory studies suggest a role in appetite suppression and weight management, likely mediated through central melanocortin pathways.
Metabolic disease management
72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 underlying claimsObservational studies have explored the management of blood sugar levels and other metabolic parameters in diabetic populations.
Reproductive & hormonal
Sexual desire & arousal regulation
40/100Rated 40/100Source typeVendor / seller pageIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 34 underlying claimsResearch suggests this peptide targets central brain pathways to regulate sexual motivation, desire, and the emotional aspects of intimacy.
Erectile function support
50/100Rated 50/100Source typeUnclassified sourceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 30 underlying claimsStudies indicate potential benefits for penile erection and sexual satisfaction, particularly in individuals who have not responded to standard oral therapies.
Research examples
- Induction of erections in men with erectile dysfunction (including non-responders to sildenafil)
- Pro-erectile effects in men (off-label)
- Synergistic Improvement in Erection Duration with PDE5 Inhibitors
Hypoactive sexual desire treatment
40/100Rated 40/100Source typeVendor / seller pageIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 18 underlying claimsClinical research has focused on the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, aiming to increase desire and reduce associated distress.
Reproductive hormone regulation
40/100Rated 40/100Source typeVendor / seller pageIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 9 underlying claimsEvidence suggests the peptide may influence the release of hormones such as oxytocin, LH, and testosterone, potentially modulating the hormonal environment related to sexual health.
Endocrine & reproductive condition support
72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 4 underlying claimsLimited evidence suggests potential off-label utility for managing symptoms related to hormonal imbalances, such as polycystic ovary syndrome (PCOS) or hypogonadism.
Thyroid function support
72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 1 underlying claimPreliminary research suggests a possible role in the management of underactive thyroid conditions.
Performance & recovery
Formulation & delivery optimization
30/100Rated 30/100Source typeVendor / seller pageIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 3 underlying claimsResearch highlights specific delivery methods, such as intranasal administration, for rapid absorption and onset of action.
Quality & manufacturing standards
40/100Rated 40/100Source typeUnclassified sourceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 underlying claimsDocumentation emphasizes the production quality and purity of the synthetic peptide for experimental consistency.
Anti-inflammatory & neuroprotective signaling
40/100Rated 40/100Source typeVendor / seller pageIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 4 underlying claimsAnimal models suggest the compound may modulate inflammatory cytokines and offer protective signaling in conditions involving the nervous system, such as stroke or spinal cord injury.
Cardiovascular safety profile
50/100Rated 50/100Source typeUnclassified sourceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 1 underlying claimClinical observations suggest a lack of interaction with the cardiovascular system, distinguishing it from other sexual dysfunction treatments.
Central nervous system activation
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 16 underlying claimsResearch points to a central mechanism of action involving the activation of specific melanocortin receptors in the brain to initiate sexual responses, rather than acting directly on blood vessels.
Growth hormone secretion
40/100Rated 40/100Source typeUnclassified sourceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 underlying claimsStudies often reference the stimulation of growth hormone release, typically in the context of combined peptide therapies.
Skin pigmentation effects
60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 underlying claimsResearch indicates that activation of specific receptors may lead to skin darkening (tanning) as a side effect of the therapy.
Sleep & stress modulation
40/100Rated 40/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 3 underlying claimsResearch has investigated interactions with sleep-regulating peptides and potential anti-stress effects, though these are often attributed to combined therapies.
Anticancer potential
30/100Rated 30/100Source typeForum or blogIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 1 underlying claimEarly-stage laboratory research has investigated potential effects on tumor cell activity, specifically in glioblastoma models.
Free: The Peptide Stack Cheat-Sheet
You just read the research on Bremelanotide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
How People Use It
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
- Single administration demonstrating effects lasting up to 24 hours 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- HyperpigmentationModerateReported in 4 sources 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pubmed.ncbi.nlm.nih.gov↗ peptidesexplorer.com↗ wellsrx.com↗ peptok.ai
- Changes in blood pressureModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ healthline.com
- Cardiovascular risksSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ healthline.com
- CoughMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ vyleesi.com
- ParesthesiaMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- PriapismSevereReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ peptidepedia.org
- Melanoma riskLifeThreatening 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- Flushing and facial rednessMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- Transient systolic blood pressure increaseMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- Mole darkeningModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- MelanomaLifeThreatening 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get Bremelanotide
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Technical Details (sequence & mechanism — click to expand)
Mechanism of Action
Bremelanotide (PT-141) is a synthetic cyclic heptapeptide melanocortin receptor agonist (principally MC4R) that acts in the central nervous system to increase sexual desire. Unlike hormonal treatments, it works via the melanocortin pathway. It is FDA-approved (Vyleesi) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Evidence
Research Citations (15)
Every claim above traces back to a source you can check — here are 15 of them.
- Source
Bremelanotide for Treatment of Female Hypoactive Sexual Desire
Review2022 Key study 86/100Rated 86/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Vyleesi (bremelanotide) prescribing information
Guideline2019 90/100Rated 90/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Bremelanotide
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
PubChem - Compound - Bremelanotide
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Vyleesi- bremelanotide injection
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
the original
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Bremelanotide
72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.
2022 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.
2022 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
PT-141 Palatin.
2004 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Bremelanotide: an overview of preclinical CNS effects on female sexual function.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Bremelanotide | C50H68N14O10 | CID 9941379 - PubChem
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
News
Latest on Bremelanotide
Dated, sourced reporting that mentions Bremelanotide.
Peak Performance Peptides - 735127 - 08/24/2026 | FDA
The FDA issued a warning letter to Peak Performance Peptides, an online seller, for marketing unapproved injectable peptide drugs including retatrutide, semaglutide, PT-141, tesamorelin, and SS-31 via its website. The agency stated these products are unapproved new drugs under the FD&C Act and warned of possible seizure or injunction if violations are not corrected. The letter highlights ongoing FDA scrutiny of grey-market peptide sellers.
TXP Innovations LLC dba Tex Peptides - 735067 - 08/24/2026 | FDA
The FDA issued a warning letter to TXP Innovations LLC (dba Tex Peptides) after reviewing its website in July 2026 and finding it marketed unapproved injectable peptide drugs, including semaglutide, tirzepatide, retatrutide, SS-31 (elamipretide), tesamorelin, and PT-141 (bremelanotide). The agency deemed these unapproved new drugs under section 505(a) of the FD&C Act. The letter warns that continued violations could trigger seizure or injunction. It underscores FDA's ongoing crackdown on unapproved peptide products sold directly to consumers online.
Peptide Partners LLC - 735063 - 08/24/2026 | FDA
The FDA issued a warning letter to Peptide Partners LLC for marketing unapproved peptide drugs, including semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin, and PT-141, via its website. The agency stated these products violate the Federal Food, Drug, and Cosmetic Act as unapproved new drugs. The letter highlights the risks of injectable unapproved products and warns of potential seizure or injunction if violations persist.
Wondering how Bremelanotide pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Related on The Health Stacks
Compare